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Abstract With the aim to identify cyclin B1-derived
peptides with high affinity for HLA-A2, we used three in
silico prediction algorithms to screen the protein sequence
for possible HLA-A2 binders. One peptide scored highest
in all three algorithms, and the high HLA-A2-binding
affinity of this peptide was verified in an HLA stabilization
assay. By stimulation with peptide-loaded dendritic cells a
CTL clone was established, which was able to kill two
breast cancer cell lines in an HLA-A2-dependent and
peptide-specific manner, demonstrating presentation of the
peptide on the surface of cancer cells. Furthermore, blood
from cancer patients and healthy donors was screened for
spontaneous T-cell reactivity against the peptide in IFN-c
ELISPOT assays. Patients with breast cancer, malignant
melanoma, or renal cell carcinoma hosted powerful and
high-frequency T-cell responses against the peptide. In
addition, when blood from healthy donors was tested,
similar responses were observed. Ultimately, serum from
cancer patients and healthy donors was analyzed for anti-
cyclin B1 antibodies. Humoral responses against cyclin B1
were frequently detected in both cancer patients and
healthy donors. In conclusion, a high-affinity cyclin B1-
derived HLA-A2-restricted CTL epitope was identified,
which was presented on the cell surface of cancer cells, and
elicited spontaneous T-cell responses in cancer patients and
healthy donors.
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Introduction
It is well established that tumor cells express tumor-asso-
ciated antigens (TAAs), and that TAA-derived peptides are
presented in context of human leukocyte antigen (HLA)
molecules and recognized by T cells. A high number of
TAAs have been characterized and cytotoxic T-lympho-
cyte (CTL) epitopes from these identified [1]. Several of
these epitopes have been tested in clinical vaccination tri-
als, and some promising clinical responses have been
observed [2–4]. Nevertheless, clinical responses remain
infrequent; thus, therapeutic anti-cancer vaccination has
not yet met its promise. One reason is the ability of cancer
cells to escape the immune system by loss or down-regu-
lation of antigens [5]. To this end, targeting of TAAs
important for survival and growth of tumor cells (such as
for example survivin [6] and telomerase [7]) may minimize
the risk of tumor immune escape.
Cyclin B1 is one of the key regulators of the cell cycle,
regulating the transition from G2 to M phase in complex
with the cyclin-dependent protein kinase cdc2. Cyclin B1
expression initiates during S-phase, peaks at G2/M phase,
and at the end of mitosis cyclin B1 is rapidly degraded [8].
Cyclin B1 is needed for cells to enter mitosis, and therefore
essential for growth of all cells, including tumor cells.
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Thus, immune escape by down-regulation or loss of
expression of cyclin B1 would impair sustained tumor cell
growth. As a consequence, cyclin B1 is an attractive target
for anti-cancer immune therapy.
In normal cells, cyclin B1 is expressed at almost unde-
tectable levels; however, many tumors express high con-
stitutive levels of cyclin B1, which causes uncontrolled
tumor growth [9]. This overexpression has been observed
in several human solid tumors, for example, breast cancer
(BC), malignant melanoma (MM), and renal cell carci-
noma (RCC) [8, 10–12], as well as some hematological
cancers [13]. In normal cells, cyclin B1 is restricted to the
nucleus, whereas it accumulates in the cytoplasm in tumor
cells [8, 14]. This causes increased degradation by the
ubiquitin pathway, which leads to increased presentation of
cyclin B1-derived peptides on the surface of cancer cells
compared with normal cells [8], which in turn may lead to
more efficient T-cell recognition. The overexpression of
cyclin B1 as well as the cytoplasmic localisation in cancer
cells compared with normal cells makes cyclin B1 a good
target candidate for anti-cancer immune therapy.
The cyclin B1-derived T-cell epitopes described so far
have been of low HLA-binding affinity. In the present
study, a high-affinity cyclin B1-derived peptide restricted
by HLA-A2 was selected using in silico peptide prediction
algorithms. The predicted high binding affinity to HLA-A2
was validated experimentally, and a CTL clone was
established that was able to kill cyclin B1-overexpressing
BC cell lines in an HLA-A2-dependent and peptide-spe-
cific manner. Also, peptide-specific spontaneous CD8?
T-cell responses as well as anti-cyclin B1 antibody responses
were observed in both healthy donors and patients with BC,
MM, or RCC.
Materials and methods
Cancer patients and healthy donors
Peripheral blood lymphocytes (PBLs) from end-stage BC
patients, RCC patients, and MM patients were used in the
study. The PBLs were obtained from the University Hos-
pital Herlev as leukapheresis products, depleted of mono-
cytes (by adherence). The cells were cryopreserved at
-150C in fetal calf serum (FCS; GibcoBRL) containing
10% dimethyl sulfoxide (DMSO; Sigma-Aldrich). Tissue
typing was conducted at the Department of Clinical
Immunology, Copenhagen University Hospital. Informed
consent was obtained from the patients before any of these
measures.
Blood from healthy donors was obtained from the blood
bank at Copenhagen University Hospital. Peripheral blood
mononuclear cells (PBMCs) were isolated by density
centrifugation on LymphoprepTM (Axis-Shield PoC). The
PBMCs were cryopreserved at -150C in FCS and 10%
DMSO.
Serum from healthy donors (26–36 years of age) and
cancer patients (36–81 years of age) was obtained from
University Hospital Herlev. Blood was allowed to coagu-
late, spun down, and serum was removed.
Cell lines
The human T2 cell line (CRL-1992) is a hybrid of the
B-lymphoblastoid cell line, B-LCL.174, and the T-lympho-
blastoid cell line, T-LCL CEM. It synthesizes HLA-A2.1
and HLA-B51.1, but does not express normal amounts on
the cell surface due to lack of functional transporter asso-
ciated with antigen processing (TAP) heterodimers. The
cell lines MDA-MB-231 (HTB-26) and CAMA-1 (HTB-
21) are HLA-A2? BC cell lines, and ZR-75-1 (CRL-1500)
is an HLA-A2- BC cell line. K562 (CCL-243) is a chronic
myelogenous leukemia cell line, which is HLA- and sen-
sitive to NK-cell-mediated killing. All cell lines were
purchased from American Type Culture Collection
(ATCC) and cultured in RPMI 1640 medium (GibcoBRL)
containing 10% FCS. All cell lines are routinely tested for
mycoplasma using a PCR-based method, and the mor-
phology is checked visually by microscope.
Peptides and peptide prediction
The Cyclin B1-derived peptide CB204 (ILIDWLVQV) and
the control peptide HIV-1 pol476-484 (ILKEPVHGV) were
both purchased from GenScript Corporation. CB204 was
selected using the in silico peptide prediction algorithms
SYFPEITHI [15], NetMHC [16, 17], and BIMAS [18].
HLA stabilization assay for peptide binding to HLA
class I molecules
HLA-A2-binding affinity of the CB204 peptide was carried
out as described elsewhere [19, 20]; only the lysis buffer
was modified from Andersen et al. (Mega-9 was excluded
and the protease inhibitors used were 5 mM iodoaceta-
mide, 2 lg/ml pepstatin and 200 lg/ml pefabloc; Boeh-
ringer Mannheim). In short, the HLA stabilization assay is
based on stabilization of HLA class I molecules after
loading of different concentrations of peptide. T2 cells
were metabolically labeled with [35S]-methionine (Amer-
sham). Stably folded HLA class I molecules were immune-
precipitated and separated by isoelectric focusing (IEF) gel
electrophoresis. HLA heavy chain bands were quantified
using the FLA-3000 phosphorimager and the Multi Gauge
V3.1 software from Fujifilm. The intensity of each band is
directly related to the amount of peptide-HLA class I
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complex recovered during the assay. The recovery of HLA-
A2 was measured in the presence of 40, 4, 0.4, and
0.04 lM of the relevant peptide, and compared with the
high-affinity HIV-1 pol476–484 peptide. The experiment was
performed twice, and within each experiment HLA-A2
stabilization (arbitrary units) was normalized to the HIV
control containing 40 lM HIV peptide.
Establishment of antigen-specific T-cell cultures
and clones
Autologous dendritic cells (DCs) were used to stimulate
PBLs from a RCC patient. DCs were generated from
monocytes, derived from a leukapheresis product, by
adherence on culture dishes at 37C and 5% CO2 for 1 h in
RPMI 1640 containing 10% human serum (Sigma). The
adherent monocytes were cultured in the presence of 250 U/
ml IL-4 and 1,000 U/ml GM-CSF (Leucomax, Shering
Plough) for 6 days. Next, the DCs were matured with
10 ng/ml IL-1b, 10 ng/ml IL-6, 10 ng/ml TNF-a (CellGe-
nix), and 1 lg/ml PGE2 (Pfizer). The phenotype of the DCs
used were characteristic for mature myeloid DCs. FACS
analysis showed a high expression of CD11c (100%), CD33
(99%), CD40 (95%), CD54 (99%), CD80 (83%), CD83
(97%), CD86 (98%), CCR7 (71%), HLA-A2 (100%), and
HLA-DR (98%), and a minor expression of CD1a (1%).
PBLs were stimulated with irradiated (25 Gy), peptide-
loaded autologous DCs (PBL:DC ratio = 3 9 106:3 9
105) and cultured in X-vivo medium (Bio Whittaker) with
5% human serum. The following day, 5 ng/ml IL-7 and
100 pg/ml IL-12 (PeproTech) were added. After 1 week
5 ng/ml IL-7 was added, and after additional 5 days, the
culture was stimulated with DCs as on day one. The next
day, 5 ng/ml IL-7 and 100 pg/ml IL-12 were added. After
1 week, the culture was stimulated with irradiated (25 Gy),
peptide-loaded autologous PBLs (culture:PBL ratio =
1.5 9 106:2 9 106), and the following day 40 U/ml IL-2
(PeproTech) was added. A fourth stimulation with PBLs
and IL-2 was given after an additional week, and the
following week the culture was tested for specificity for
CB204 in a 51Cr-release assay.
The specific culture was cloned by limiting dilution in
the presence of 105 cloning mix cells and 120 U/ml IL-2.
Cloning mix was prepared from irradiated (25 Gy) PBMCs
from three healthy donors, which were mixed at a con-
centration of 106 cells/ml and stimulated with phytohem-
agglutinin (PeproTech) for 2 h. Clones were administered
120 U/ml IL-2 every 3–4 days.
Cytotoxicity assay
Conventional 4 h 51Cr-release assays for CTL-mediated
cytotoxicity were carried out as described elsewhere [21].
In brief, target cells were labeled with Na2
51CrO4 (Perkin
Elmer) for 1 h, washed, and co-cultured with the effector
cells for 4 h. Next, the level of 51Cr in the supernatants was
measured using a Perkin Elmer Wallac Wizard 1470
automatic gamma counter. Target cells were cancer cell
lines or peptide-loaded T2 cells. Lysis was inhibited in a
cold target inhibition assay using unlabeled, peptide-loaded
T2 cells. Inhibitor:target ratio was 20:1.
Subcellular fractionation of cancer cell lines
and western blot
4 9 106 cells were washed in PBS, pelleted, suspended in
cytoplasmic lysis buffer [10 mM Hepes pH 7.5, 2 mM
MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM KCL, 1 mM
Dithiothreitol (DTT), 10 mM NaF, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF)], and incubated for 15 min at
4C. Next, Nonidet P-40 (NP-40) was added, samples were
incubated for 15 min at 4C, and centrifuged at
10,0009g for 10 min at 4C. The supernatant was har-
vested (cytoplasmic fraction). The pellet was suspended in
nuclear lysis buffer (20 mM Hepes pH 7.5, 500 mM NaCl,
10% glycerol, 0.2% NP-40, 1 mM DTT, 10 mM NaF,
1 mM PMSF), and centrifuged at 10,0009g for 15 min at
4C. The supernatant was harvested (nuclear fraction).
The cytoplasmic and nuclear fractions were subjected to
western blotting as described previously [22]. The mem-
brane was cut into three pieces for incubation with anti-
cyclin B1 antibody (BD, 554176), anti-PARP antibody
(nuclear loading control; Cell signaling, 9542), or anti-
actin antibody (cytoplasmic loading control; Sigma,
A3853). To ensure equal loading, the total protein con-
centration of each sample was determined by Bradford
Protein Assay (Bio-Rad).
Interferon-c (IFN-c) ELISPOT assay
The IFN-c ELISPOT assay was used to quantify peptide-
specific IFN-c-releasing effector cells, as described previ-
ously [23]. Before analysis, PBMCs or PBLs were stimu-
lated once in vitro with 20 lM peptide to extend the
sensitivity of the assay [24]. The following day, 40 U/ml
IL-2 was added, and after 7–8 days in culture, the cells
were tested for reactivity. Briefly, nitrocellulose-bottomed
96-well plates (MSIPS4 W, Millipore) were coated with
anti-IFN-c antibody (Mabtech, 1-D1 K). The wells were
washed and blocked with X-vivo medium. Effector cells
were added in duplicates, at different cell concentrations
(1 9 105, 3 9 105, and 5 9 105 cells per well), with or
without 5 lM peptide. Also, 104 T2 cells were added per
well. The plates were incubated overnight. The following
day, the wells were washed and incubated with biotinylated
secondary antibody (Mabtech, 7-b6-1) for 2 h. Next, the
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wells were washed, and avidin-enzyme conjugate (strep-
tavidin–alkaline phosphatase conjugate, Mabtech) was
added. The plates were incubated for 1 h, before the wells
were washed, and enzyme substrate (NBT/BCIP, Mabtech)
was added. The plates were incubated at room temperature
for up to 5 min. Upon emergence of dark purple spots, the
reaction was stopped by washing with tap water. The spots
were counted using an ImmunoSpot Analyzer plate reader
and the software ImmunoCapture 6.0 and ImmunoSpot
professional satellite 4.0.17 (C.T.L. Cellular Technology
Ltd.). The peptide-specific CTL frequency was calculated
as the average number of peptide-specific spots formed in
the ELISPOT assay, i.e., the number of spots formed in the
wells with no added peptide, subtracted from the number of
spots formed in wells with CB204. A response was defined
as the average number of peptide-specific spots ±
SD [25 spots per 105 PBLs/PBMCs.
Cyclin B1 ELISA
96-well plates (Nunc, Thermo Scientific) were coated with
0.65 lg of recombinant human cyclin B1 protein (Santa
Cruz Biotechnology) in 50 ll PBS and incubated overnight
at 4C. Plates were washed with PBS and blocked with
2.5% BSA in PBS (blocking buffer) for 1 h. Blocking
buffer was discarded and 100 ll of diluted serum was
added to each well (dilution 1:200). The plates were
incubated for 1 hour at room temperature and then washed
with 1% Tween in PBS. Next, 100 ll anti-human IgG
antibody conjugated to alkaline phosphatase (Sigma) was
added to each well and the plates were incubated for 1 hour
at room temperature. Plates were washed and 100 ll
alkaline phosphatase yellow liquid substrate (Sigma) was
added. Plates were incubated 1 hour at room temperature in
the dark, and the reaction was stopped with 50 ll 3 M
NaOH. Absorbance was read at 405 nm. Background for
each sample was measured in uncoated wells and sub-
tracted from each sample before it was normalized to a
positive control (serum from a MM patient that was found
to give an absorbance of 1.35 in the ELISA).
Results
Patient characteristics
Patient samples were collected upon inclusion in four dif-
ferent vaccination trials [25–27]. Disease progression was a
common inclusion criterion. All but one patient had
received prior treatments, but no patients suffered from
other malignancies. The MM patients (n = 6, age 36–81, 4
females, 2 males) all had metastatic disease (ranging from
5 to 229 months), and had metastases at two, three or four
sites. One patient was treatment naive, but remaining five
received prior treatment with electro-chemotherapy, IL-2
and INF-a, or DC vaccination. The patients with RCC
(n = 6, age 49–65, 1 female, 5 males) had from one to
three metastases. Most of them received prior treatment
with IL-2 in combination with INF-a. BC patients from two
different trials were included (n = 10, age 44–64). In one
trial the patients (n = 4) had from one to six metastases.
They all received prior treatment with endocrine regimes
and one patient with chemotherapy as well. The other trial
was quickly closed due to disease progression (n = 6). All
patients had multiple metastases and received prior treat-
ment with several lines of standard chemotherapy.
Peptide binding to HLA-A2
In silico peptide prediction algorithms were used to predict
cyclin B1-derived peptides with high affinity for HLA-A2.
The three algorithms SYFPEITHI [15], NetMHC [17], and
BIMAS [18] were used, and they all predicted the peptide
CB204 to bind HLA-A2 with the highest affinity compared
with other cyclin B1-derived nonameric peptides. The
binding affinity of the CB204 synthetic peptide was studied
in an HLA stabilization assay (Fig. 1). Compared with a
high-affinity HIV-derived positive control peptide, the
CB204 peptide bound with very high affinity to HLA-A2.
CTL killing of cancer cells
PBLs from a RCC patient were stimulated twice with
peptide-loaded autologous DCs, following two stimulations
with peptide-pulsed PBMCs. The peptide-specific culture
was cloned by limiting dilution. A CB204-specific clone
Fig. 1 Stabilization of HLA-A2 by CB204 analyzed using an HLA
stabilization assay. HIV is a high-affinity peptide (HIV-1 pol476–484)
used as positive control. CB204 stabilizes HLA-A2 to a higher degree
than HIV, and therefore binds to HLA-A2 with very high affinity. The
graph shows the mean value from two experiments, where HLA-A2
stabilization units have been normalized to HIV (40 lM peptide)
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was established, which was able to lyse T2 cells loaded
with CB204, but not T2 cells loaded with an irrelevant HIV
peptide (Fig. 2a). The CTL clone was also capable of
killing two HLA-A2? BC cell lines, but did not lyse the
HLA-, NK-sensitive cell line K562 (Fig. 2b). In addition,
a cold target inhibition assay indicated peptide-specific and
HLA-A2-restricted lysis, since the cold target cells pre-
senting CB204 inhibited lysis of cancer cells, whereas the
cold target cells presenting an irrelevant peptide did not
(Fig. 2c). Furthermore, the CTL clone was not able to kill
an HLA-A2- BC cell line, again indicating HLA-A2-
restricted lysis (Fig. 2c). Fig. 2d shows that cyclin B1 was
expressed in the three BC cell lines used as target cells.
Cyclin B1 expression was observed in both cytoplasm and
nucleus in the cell lines, although at different levels. This
indicated overexpression of cyclin B1 in all three BC cell
lines.
Altogether, there was strong evidence for processing and
presentation of the CB204 peptide on the cell surface of BC
cells in context of HLA molecules.
Spontaneous T-cell responses against CB204
Spontaneous T-cell reactivity against the CB204 peptide
was analyzed in an IFN-c ELISPOT assay using PBLs from
cancer patients. A high frequency of patients with BC,
MM, or RCC hosted powerful spontaneous T-cell respon-
ses against the peptide (Fig. 3). In fact, seven out of ten BC
patients, five out of six patients with MM, and four out of
six RCC patients hosted a T-cell response against CB204.
When PBMCs from healthy donors were tested, powerful
and frequent responses were also observed (Fig. 3). 10 out
of 11 healthy donors hosted a response against CB204.
Humoral immune responses against CB204
Serum samples from cancer patients and healthy donors
were screened for anti-cyclin B1 responses. Cyclin B1 IgG
Fig. 2 Cytotoxic capacity of a CB204-specific CTL clone analyzed
with a conventional 4-h 51Cr-release assay. E:T means effector to
target ratio. The irrelevant peptide used is HIV-1 pol476–484.
a Peptide-specific killing of T2 cells loaded with CB204. The
experiment was performed in singlets. b Killing of the HLA-A2? BC
cell lines CAMA-1 and MDA-MB-231. K562 is an HLA- cell line,
sensitive to NK-mediated killing. The experiment was performed in
singlets, but it was repeated with similar results, however, with
slightly lower lysis (max. lysis of CAMA-1 was 29%, and of MDA-
MB-231 28%). c Cold target inhibition assay with 20 times as many
cold (non-radioactively labeled) T2 cells added. ZR-75-1 is an HLA-
A2- BC cell line. The experiment was performed in singlets.
d Subcellular fractionation and western blot analysis showing the
subcellular location of cyclin B1 in the BC cancer cell lines used as
targets in the 51Cr-release assay. PARP was used as loading control
for the nuclear fraction (N) and Actin for the cytoplasmic fraction (C)
b
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could be detected in all patients and all healthy donors
(Fig. 4). However, it was not possible to determine the
objective cut-off point between the true antibody positive
and negative individuals, because all samples were positive
compared with the background control values. However, it
is clear that anti-cyclin B1 responses were present in both
cancer patients and healthy donors.
The level of anti-cyclin B1 antibody varied between the
different individuals, but was similar between patients and
healthy donors. In patients, the normalized absorbance
(405 nm) ranged from 0.10 to 1.78, and in healthy donors
the range was from 0.38 to 1.34.
Discussion
Due to the phenomenon of ‘‘immune escape’’, strategies are
being developed that conceptually focus on minimizing the
risk of immune escape by specifically targeting proteins that
are important for the function, survival, and growth of cancer
cells. Cyclin B1 represents such a protein, and Kao et al. [14]
have described immunogenic, HLA-A2-restricted peptides
derived from cyclin B1. These peptides were characterized
by elution of peptides from cancer cells; thus, the expression
of the peptides on the cell surface of cancer cells was firmly
established. The epitopes identified were, however, of low
affinity to HLA. In the present study, reverse immunology
was used to identify a high-affinity CTL epitope. First, the
amino acid sequence of the cyclin B1 protein was screened
for the most probable HLA-A2 nonameric peptide epitopes
using different CTL epitope prediction algorithms. The
peptide CB204 was selected and an HLA stabilization assay
showed that the peptide had very high affinity for HLA-A2.
To verify the presence of the peptide on the cell surface of
cancer cells, a CB204-specific CTL clone was established.
The clone was able to lyse cyclin B1-overexpressing tumor
cells in a peptide-specific and HLA-A2-restricted manner,
showing that CB204 was presented in context of HLA-A2
molecules on the surface of cancer cells.
Additionally, we detected spontaneous T-cell responses
against the CB204 peptide in 73% of the cancer patients
tested and 90% of the healthy donors that were analyzed.
These cells were most likely of an antigen-experienced
phenotype, since they were able to produce IFN-c upon
stimulation with the CB204 peptide alone. Furthermore,
anti-cyclin B1 antibody responses were detected in all
cancer patients and healthy donors analyzed, but it was, as
mentioned, not possible to determine the cut-off between
Fig. 3 T-cell responses against the CB204 peptide analyzed in an
IFN-c ELISPOT assay. PBLs from ten patients with BC, six MM
patients, six RCC patients, and PBMCs from eleven healthy donors
were tested. The cell concentration was 3 9 105 cells per well, and
the ELISPOT plates were incubated overnight. Measurements were
performed in duplicates. Each dot represents a CB204-specific
response, where the background has been subtracted. A response
was defined as the average number of peptide-specific spots ±
SD [25 spots per 105 PBLs/PBMCs
Fig. 4 Humoral responses against cyclin B1 analyzed by ELISA.
Sera from ten patients with BC, six MM patients, six RCC patients,
and ten healthy donors were tested. The cancer patients were the same
as used in the analysis of CB204-specific T-cell responses (Fig. 3),
but the healthy donors were different from those used for Fig. 3. The
absorbance reading at 405 nm (A405) corresponds to the amount of
cyclin B1-specific antibody present in the serum. Each dot represents
an anti-cyclin B1 response, where the background from uncoated
wells has been subtracted. All samples have been normalized to a
positive control serum. Four replicas were included for each sample
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true positive and negative individuals in the ELISA assay.
Nevertheless, frequent humoral responses against cyclin
B1 were detected in both patients and healthy donors.
There were, however, no correlation between the T-cell
responses and the antibody responses detected in the patients.
Also, there was no correlation between patient disease pro-
gression/prior therapies/age and immune responses.
Cyclin B1-specific T cells and antibodies in cancer
patients have been observed by others [14, 28]. In addition,
Vella and co-workers [29] reported the presence of cyclin
B1-specific CD8? T cells in healthy donors. These T cells
in healthy donors were also antigen-experienced based on
their IFN-c production. They also detected anti-cyclin B1
antibodies (IgG) in the healthy donors, corresponding with
our results. Suzuki and coworkers [28] detected signifi-
cantly lower levels of anti-cyclin B1 antibody in healthy
donors than in cancer patients. This is contrary to our
findings, where the levels were similar in all individuals.
This difference may be explained by different assay pro-
tocols and use of different secondary antibodies. Suzuki
and coworkers used an antibody detecting IgM, IgG, and
IgA, whereas we only detected IgG. Maybe the predomi-
nant isotype in healthy donors is IgG, and in cancer
patients the other isotypes are dominant as well.
In addition to cyclin B1-specific CD8? T cells and anti-
bodies, Vella et al. also reported the presence of CD4? T
cells in healthy donors. Thus, there seems to be extensive
both humoral and cellular immune responses against cyclin
B1 in healthy donors as well as cancer patients. This could
indicate that anti-cancer immune therapy targeting cyclin
B1 would be safe and not cause autoimmunity. Furthermore,
the level of peptide-HLA complexes on the cell surface of
normal cells is possibly too low to reach the threshold for
immune detection. However, in cancer cells, overexpression
of cyclin B1 leads to increased presentation of the peptide on
the cell surface and thus T-cell recognition. This difference
in expression would explain why cyclin B1-specific T cells
in healthy donors do not cause autoimmunity, and why
T-cell responses against normal cells should not be expected
in cancer patients treated with cyclin B1-targeted immuno-
therapy. However, the question as to why cyclin B1 —and
some other TAA—elicits immune responses in normal
healthy donors remains elusive.
In the study by Vella et al. [29], mice bearing cyclin B1-
overexpressing tumors were vaccinated using a protein-
based vaccination strategy. They observed induction of
cyclin B1-specific CD4? and CD8? T cells and antibodies,
lower tumor volume, increased survival of the mice, and no
signs of autoimmunity. Although this was a mouse study
and long-term effects could not be studied, it strongly
supports cyclin B1 as an ideal target for anti-cancer vac-
cination and also indicates that it would be safe to induce
an immune response directed against cyclin B1.
Besides indicating that cyclin B1-targeted anti-cancer
immune therapy is safe, responses in healthy donors may
also indicate that cyclin B1-targeted anti-cancer vaccina-
tion would have a higher efficacy due to a higher precursor
frequency of cyclin B1-specific T cells. Rizzutto and
coworkers [30] recently reported that, in mice, there is a
correlation between the frequency of self-antigen-specific
CD8? T-cell precursors and the quality of the anti-cancer
immune response. Mice challenged with the melanoma cell
line B16F10 were adoptively administered different num-
bers of gp100-specific CD8? T cells obtained from pmel-1
transgenic mice. Afterwards, the mice received three
weekly vaccinations with plasmid encoding gp100. This
experiment showed that gp100-specific CD8? T-cell pre-
cursor frequency was a significant predictor of treatment
outcome. They observed both a better proliferation of
autologous antigen-specific T cells in the mice, and also a
higher frequency of poly-functional effector cells. In
addition, the treated mice had a longer tumor-free survival
period, and a higher frequency of memory cells 85 days
after the last vaccination. If this translates to humans,
cyclin B1 responses in healthy donors may be a good
prognostic factor for successful anti-cancer vaccination.
The fact that immune reactivity against cyclin B1 is
observed in healthy donors could mean that cancer patients
have a higher frequency of cyclin B1-specific CD8? T-cell
precursors in the blood, in turn leading to a higher efficacy
of cyclin B1-targeted anti-cancer vaccination.
In conclusion, cyclin B1 is a promising target for anti-
cancer vaccination and maybe even for adoptive transfer of
cyclin B1-specific T cells. Further studies should therefore
be performed, aiming at characterizing cyclin B1-specific
T cells in healthy donors further, as well as identifying
CTL epitopes restricted to other HLA-alleles.
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